← Russell 3000 cross-section

DERM Journey Medical Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-12, not restated
Healthcare

Scale

Market cap
$213m
Revenue TTM
$67m
Net income TTM
$-6m
Free cash flow
Composite score
Sector rank
#2842

Valuation

P / E
EV / EBITDA
EV / sales
3.1
FCF yield
Earnings yield vs 10-yr
-7.60pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-9.1%
EBITDA margin
ROE
-19.0%
ROIC
-11.2%
Revenue growth
20.7%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We are also a “smaller reporting company,” meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. Results of Operations The following table summarizes our results of operations for the three-month periods ended June 30, 2026 and 2025: Comparison of the Three-Month Periods Ended June 30, 2026 and 2025 ​ ​ Revenues The following table reflects our net product revenue for the three-month periods ended June 30, 2026 and 2025: ​ ​ Net product revenue increased $2.8 …Journey Medical Corp, 10-Q, period ended 2026-06-30, filed 2026-08-12

Read the full passage →